In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sorrento Therapeutics, Inc.

https://sorrentotherapeutics.com/

Latest From Sorrento Therapeutics, Inc.

Sorrento, Under Shadow Of Chapter 11, Looks To Move BTK Inhibitor Into Phase III

The biotech announced promising Phase IIa results for abivertinib in marginal zone lymphoma and is in talks with Chinese regulators about a Phase III trial.

Clinical Trials Business Strategies

US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar

Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair. Use of decentralized mode for its Phase III trials is a notable aspect.

Sales & Earnings Strategy

US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar

Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect

Commercial Sales & Earnings

Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes

Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.

Deals M & A
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Saliva-based Testing
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • ADNAB, Inc.
    • Levena (Suzhou) Biopharma Co., Ltd
    • SCILEX Pharmaceuticals, Inc.
    • Scilex Holding Company
    • Scintilla Pharmaceuticals, Inc.
    • Semnur Pharmaceuticals, Inc.
    • Sherrington Pharmaceuticals
    • SmartPharm Therapeutics, Inc.
    • TNK Therapeutics, Inc.
    • Virttu Biologics Limited
UsernamePublicRestriction

Register